COMMUNIQUÉS West-GlobeNewswire

Intelligent Bio Solutions Advances Preparations and Provides Updated Timeline for Anticipated FDA 510(k) Submission and Clearance
26/09/2025
The Company is initiating clinical studies to further validate Intelligent Fingerprinting Drug Screening System INBS anticipates FDA 510(k) clearance in the second half of 2026 NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE [...]
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
26/09/2025
CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex [...]
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
26/09/2025
CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
26/09/2025
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal BRIDGEWATER, N.J., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or [...]
Aveanna to Participate at the Deutsche Bank Annual Leveraged Finance Conference
26/09/2025
ATLANTA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Deutsche Bank Annual Leveraged Finance Conference in [...]
ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
26/09/2025
MIAMI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, today announced it has been awarded a $2.5 million Phase II [...]
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
26/09/2025
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a [...]
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
26/09/2025
FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-density lipoprotein [...]
Sanuwave Announces Strategic Debt Refinancing with New Credit Facility
26/09/2025
Credit facility from J.P. Morgan consists of a four-year term loan of $23 million and a two-year $5 million revolving credit facility backed by accounts receivable Both the term loan and revolver have an interest rate [...]
Harrow to Acquire Melt Pharmaceuticals
26/09/2025
NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to [...]
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
26/09/2025
Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regain in sham-treated [...]
ADvantage Therapeutics Awarded $2.5 milion NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
26/09/2025
MIAMI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, today announced it has been awarded a $2.5 million Phase II [...]
RadNet, Inc. to Present at the Jefferies Healthcare Services Conference on September 29, 2025
26/09/2025
LOS ANGELES, Sept. 26, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]
Dogecoin Cash, Inc. (OTCQB: DOGP) Subsidiary PrestoDoctor Expands Telehealth Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide
26/09/2025
Now Operating in 19 States Nationwide Las Vegas, NV, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide Mesquite, NV — September 26, 2025 — Dogecoin Cash, Inc [...]
BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented
26/09/2025
September 26, 2025 News Release BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented COPENHAGEN, DENMARK and BOSTON, MA, USA, September 26 – BioPorto A/S (“BioPorto” or the “ [...]
Concept Life Sciences Expands Integrated Drug Discovery Facilities
26/09/2025
Establishes one of the UK’s largest drug discovery research sites Site officially opened by local MP Jonathan Pearce CHAPEL-EN-LE-FRITH, United Kingdom, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Concept Life Sciences, a [...]
Fangzhou’s ‘XingShi’ LLM Featured by Nature News and Xinhua, Showcasing AI Innovation in Chronic Disease Care
26/09/2025
SHANGHAI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, announced that its “XingShi” Large Language Model (“XS LLM”) was [...]
Ipsen et BioLabs Hôtel-Dieu décernent le Golden Ticket Ipsen 2025 à DETERA Therapeutics
26/09/2025
Paris, le 26 septembre 2025 – BioLabs Hôtel-Dieu, en partenariat avec Ipsen, annoncent aujourd'hui que DETERA Therapeutics s'est vu décerner le Golden Ticket Ipsen 2025 . Ce prix offre un an d'accès gratuit à un [...]
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
26/09/2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products [...]

Pages